ESMO Rewards Outstanding Oncologists
The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, has revealed the four outstanding recipients of its distinguished awards.
ESMO Media Releases
ESMO Publishes Results of European Consortium Study on the Availability of Anti-neoplastic Medicines
A major new study has found substantial differences in the formulary availability, out-of-pocket costs and actual availability of anti-cancer medicines across Europe.
ESMO 2018 Annual Congress to be Held in Munich
We are pleased to announce that the ESMO 2018 Annual Congress will take place between 19-23 October 2018 at the Messe Muenchen, Germany
The Debate on the Phase 3 Trial of MABp1 Presented at the 18th ESMO World Congress on Gastrointestinal Cancer
The lively discussion which followed the presentation of ‘A pivotal phase 3 Trial of MABp1 in advanced colorectal cancer'
Results of First Study Assessing Clinical Impact of ESMO-MCBS
Details of the first study by one of Europe’s largest cancer centres, the Medical University of Vienna (MUV), assessing the clinical impact and feasibility of the ESMO Magnitude of Clinical Benefit Scale (MCBS) in a real-life context are now available on ESMO Open
ESMO Releases New Consensus Guidelines on the Management of Metastatic Colorectal Cancer
Guidelines reflect personalised treatment approach
First Oncology Society Partnership for New ESMO Open Access Journal
AIOM adopts ESMO Open as its scientific journal
Anti-Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly Over Placebo
Phase III trial finds excellent safety and tolerability
Regorafenib Shows Significant Survival Gains in Refractory Liver Cancer
Phase III trial confirms efficacy and safety of new second-line agent
Chemoradiotherapy After Surgery for Gastric Cancer Shows Similar Outcomes to Post-Operative Chemotherapy
Phase III trial finds no significant difference in overall survival
Anti-PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination with MEK Inhibition
Phase I trial achieves partial responses and is well tolerated
EMA ESMO Workshop: Optimising the use of single arm trials in cancer drug development
The European Medicines Agency (EMA) and the European Society for Medical Oncology (ESMO) will host a workshop on single-arm trials (SATs) at the EMA headquarters in London, UK, on June 30th 2016.